South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
The South Korean regulatory environment for cell and gene therapies is poised to change substantially through a new Cutting Edge Regenerative Medicine and Biologics Act to be introduced next year.
But until the new law is fully implemented in August 2020, further discussions across multiple areas will be needed to...